Welcome to our dedicated page for NovaBridge Biosciences SEC filings (Ticker: NBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NovaBridge Biosciences (NBP) SEC filings page on Stock Titan provides access to the company’s official disclosures as a foreign private issuer listed on Nasdaq. NovaBridge, formerly known as I-Mab, files reports such as Form 20-F and Form 6-K that describe its financial condition, risk factors, and operational progress as a global biotechnology platform company.
In these filings, NovaBridge outlines its business model, which combines business development and translational clinical development to advance a pipeline led by givastomig, ragistomig, uliledlimab, and VIS-101. Management’s discussion and analysis sections describe how the company allocates resources to oncology and ophthalmology programs, summarizes its collaborations with partners such as ABL Bio, and explains the structure of subsidiaries like Visara within its hub-and-spoke framework.
Investors reviewing NovaBridge’s SEC reports can examine clinical development disclosures for givastomig, including its positioning as a Claudin 18.2 x 4-1BB bispecific antibody in gastric and other gastrointestinal cancers, and for ragistomig as a PD-L1 x 4-1BB bispecific in solid tumors. Filings also discuss rights to uliledlimab outside Greater China and the VIS-101 license and assignment arrangements involving Visara and Everest Medicines.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as segment descriptions, collaboration agreements, share incentive plans, and subsequent events. Users can follow new 6-K submissions for interim updates, and consult annual filings for a more comprehensive view of NovaBridge’s strategy, risk profile, and pipeline.
By using this page, investors and researchers can monitor NovaBridge’s official SEC communications in real time, while AI-generated insights help interpret complex biotech and capital markets information contained in the original documents.
NovaBridge Biosciences furnished an investor presentation detailing its transition into a global platform biotech with four clinical-stage assets in oncology and ophthalmology. Lead asset givastomig, a CLDN18.2 x 4-1BB bispecific for first-line gastric and related cancers, showed objective response rates of 75% across 8 mg/kg and 12 mg/kg cohorts and median progression-free survival of 16.9 months at 8 mg/kg in a Phase 1b study, with responses seen even in patients with low CLDN18.2 and low PD-L1 expression.
Ophthalmology candidate VIS-101, a VEGF x Ang-2 bispecific, delivered rapid vision gains sustained beyond 16 weeks in a Phase 2 wet AMD trial after three loading doses, supporting potential best-in-class durability, with topline Phase 2 data expected in Q1 2026 and Phase 3 readiness targeted by the end of 2026. The company also highlighted encouraging early data and differentiation claims for immuno-oncology programs ragistomig (PD-L1 x 4-1BB) and uliledlimab (CD73 mAb) in solid tumors and NSCLC.
Financially, NovaBridge reported $228.3 million in cash, cash equivalents and short-term investments as of September 30, 2025, no outstanding debt, and an anticipated cash runway extending to the fourth quarter of 2028, intended to support its planned clinical development and business development activities.
NovaBridge Biosciences appointed Dr. Emmett T. Cunningham Jr., MD, PhD, MPH, as Vice Chairman of its board of directors and as a member of the Research and Development Committee, effective immediately. He is Executive Chairman and co-founder of NovaBridge subsidiary Visara and previously held senior roles at Blackstone, Clarus Ventures, Eyetech, and Pfizer.
As Vice Chairman and R&D Committee member, Dr. Cunningham will receive a $50,000 annual cash retainer, an initial stock option grant with a grant date fair value of $300,000, and ongoing equity grants under the non-executive director compensation policy. The report also highlights NovaBridge’s pipeline, including givastomig for Claudin 18.2-positive cancers, ragistomig and uliledlimab in oncology, and VIS-101 in Phase 2a for wet AMD.
NovaBridge Biosciences has enrolled the first patient in its global, randomized Phase 2 study of givastomig for first-line metastatic gastric cancer. Givastomig is a Claudin 18.2 x 4-1BB bispecific antibody given with nivolumab and mFOLFOX6 immunochemotherapy.
The company highlights prior Phase 1b combination data in HER2-negative gastric cancer, where givastomig achieved a 75% objective response rate, a 16.9-month median progression-free survival and an 82% six-month landmark PFS, with good overall tolerability. These results support the move into Phase 2.
The Phase 2 trial plans to enroll about 180 patients with CLDN18.2-positive, PD-L1–positive gastric and related cancers, randomized between two givastomig doses and control. Top-line results are expected in 2027, while detailed Phase 1b expansion data are planned for a major medical conference in the second half of 2026.
NovaBridge Biosciences filed an amended Form 6-K to furnish an updated investor presentation detailing its strategy, pipeline and finances. The company positions itself as a hub-and-spoke platform sourcing early-stage assets and driving them to clinical proof-of-concept, especially in oncology and ophthalmology.
The pipeline centers on four clinical-stage programs: givastomig (CLDN18.2 x 4-1BB bispecific) for first-line gastric and other CLDN18.2-positive cancers, ragistomig (PD-L1 x 4-1BB bispecific) for solid tumors, uliledlimab (CD73 antibody) for non-small cell lung cancer, and VIS-101 (VEGF x Ang-2 bispecific) for wet AMD and DME.
In a Phase 1b study in first-line gastroesophageal cancer, givastomig plus nivolumab and chemotherapy showed an objective response rate of 75% across 52 efficacy-evaluable patients and median progression-free survival of 16.9 months, with manageable safety. VIS-101 Phase 2 interim data in wet AMD suggest vision gains sustained beyond 16 weeks.
The presentation notes no outstanding debt and cash, cash equivalents and short-term investments of $228.3 million as of September 30, 2025, with an expected cash runway into the fourth quarter of 2028. Key upcoming events include Phase 2 VIS-101 topline data in wet AMD in the first quarter of 2026 and multiple planned studies and readouts for givastomig, ragistomig and uliledlimab through 2027.
NovaBridge Biosciences furnished an investor presentation outlining its evolving “hub-and-spoke” biotech platform, four clinical-stage assets and a strong balance sheet. Lead oncology candidate givastomig showed objective response rates around 75% and median progression-free survival of 16.9 months in first-line gastric cancer combinations.
The company is also advancing ophthalmology bispecific VIS-101, CD73 antibody uliledlimab and PD-L1×4‑1BB bispecific ragistomig, with multiple Phase 1/2 milestones in 2026–2027. NovaBridge reports no debt and cash, cash equivalents and short‑term investments of $228.3 million, guiding an operational runway to the fourth quarter of 2028.
NovaBridge Biosciences large shareholder affiliates of CBC Group, including multiple C‑Bridge and I‑Bridge funds and vehicles, filed Amendment No. 2 to Schedule 13D for the company’s ordinary shares and ADSs.
The filing shows that Wei Fu may be deemed to beneficially own 30,499,709 ordinary shares, or 11.5% of NovaBridge’s outstanding ordinary shares, based on 265,169,373 ordinary shares outstanding following an underwritten offering described in a Form 6‑K. Other reporting entities, such as C‑Bridge Healthcare Fund II, L.P. and C‑Bridge Capital GP, Ltd., report beneficial ownership stakes ranging from 0.9% to 8.8%.
The filing also explains that each ten (10) ADSs represents twenty‑three (23) ordinary shares, and notes that Nova Aqua Limited recently purchased ADSs in open‑market broker transactions, detailed in a referenced Schedule I.
NovaBridge Biosciences reports that its Chief Executive Officer, Dr. Sean Fu, intends to purchase up to $100,000 of the company’s American depositary shares in open market transactions. These purchases began on January 22, 2026, and the company notes there is no guarantee regarding the exact number of ADSs that will be acquired or the time frame over which any purchases will occur.
The report also reiterates that statements about these planned purchases and the development, strategy, safety, efficacy and anticipated milestones for drug candidates such as givastomig, ragistomig, uliledlimab and VIS-101 are forward-looking and subject to significant risks. These risks include clinical outcomes, regulatory decisions, market conditions, intellectual property protection, third-party dependencies and the company’s ability to secure additional funding, as discussed in its prior SEC filings.
NovaBridge Biosciences reports that Dr. Sean Cao, its Chief Business Development Officer and Board member, intends to purchase up to $100,000 of the company’s American depositary shares in open market transactions. These purchases began on January 21, 2026, and there is no guarantee regarding the exact number of ADSs that will be bought or the time period over which they will occur.
The company also reiterates standard forward-looking statement language, highlighting that expectations about potential ADS purchases, its drug candidates, and anticipated clinical milestones involve risks and uncertainties, including market conditions, clinical results, regulatory decisions, intellectual property protection, reliance on third parties, and its need for additional funding.
NovaBridge Biosciences reports that its Executive Chairman, Fu Wei, plans to purchase up to $5,000,000 of the company’s American depositary shares in open market transactions through an entity he controls. The purchases began on January 15, 2026, but there is no assurance on how many ADSs will ultimately be bought or over what period, since execution depends on his decisions and market conditions.
NovaBridge Biosciences reported updated Phase 1b data for its bispecific antibody givastomig in first-line HER2-negative metastatic gastric cancer, given with nivolumab and mFOLFOX6 chemotherapy. Among efficacy-evaluable patients, overall response rates were 77% (20/26) at 8 mg/kg and 73% (19/26) at 12 mg/kg, with responses seen across a wide range of CLDN18.2 and PD-L1 expression levels. Median progression-free survival reached 16.9 months at 8 mg/kg, while the 12 mg/kg cohort is less mature, with strong six‑month PFS rates of 73% and 91% in the 8 mg/kg and 12 mg/kg groups, respectively.
The safety profile was generally comparable to standard first-line regimens, with common treatment-related effects such as fatigue, nausea, and neutropenia, and no Grade 5 events reported. Immune‑related gastritis occurred in about one‑third of patients, was mostly manageable, and was associated with better outcomes. Management positions givastomig as a potential best‑in‑class CLDN18.2 therapy in a gastric cancer market the company estimates at $12 billion by 2030 and plans to start a global randomized Phase 2 trial in Q1 2026.